Partnership Designed to Bring Improved Workflow to Radiation Oncology Departments

SAN JOSE, California, April 8, 2019 /PRNewswire/ — AirXpanders, Inc. (ASX: AXP), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, and Radformation, Inc., a software company co-founded by medical physicists dedicated to bringing intelligent automation software in cancer care, including breast and breast reconstruction radiation therapy treatment planning, announced today that they have entered into a co-marketing agreement to introduce Radformation’s EZFluence software to Radiation Oncology departments that are treating AeroForm patients in the US. 

The co-marketing agreement enables AirXpanders sales personnel to introduce the EZFluence software to radiation oncology departments who are treating a growing number of patients with the AeroForm Tissue Expander System.  This collaboration is expected to improve acceptance of the AeroForm Expander by significantly improving the workflow required to develop radiation treatment plans.  By collaborating on the introduction of the EZFluence software, both organizations expect Radiation Oncology departments to benefit from the intelligent automation of radiation therapy treatment planning for breast reconstruction patients.

“We have been very impressed with the EZfluence software,” said Mark Payne, VP, Research and Development of AirXpanders. “The intelligent automation this software provides for opposed tangent fields, using both field-in-field and E-comp techniques, is impressive in its thoroughness and ability to effectively develop a radiation treatment plan in minutes from a patient CT scan.  The plans developed by this software exhibit significantly improved homogeneity compared to conventionally-determined iterative plans.  We expect radiation oncology departments will appreciate the dramatic reduction in the time needed to develop a treatment plan for patients with an AeroForm, and an overall increase in their productivity for all their breast radiation treatment plans.   We are excited to train up our team, and introduce our customer base to this advancement in radiation treatment planning automation.”

“Radformation is excited to work with a company that empowers patients and values their interests,” said Elisabeth van Wie, Medical Physicist and Chief Business Officer of Radformation.

“AirXpanders’ goal is to make the patient more comfortable during a difficult time in their lives while maintaining quality treatment.  We support this goal and look forward to working with clinics on generating optimal radiation treatment plans for patients.”

Radformation’s EZFluence is FDA cleared and available in the US since 2017.  With a rapidly growing installed base, a growing number of Radiation Oncologists and Medical Physicists are utilizing the system, and experiencing the productivity improvements it provides.  As a plug-in script for Varian’s Eclipse system, EZFluence is straightforward to use and easy to adopt.

“EZFluence is a treatment planner’s best friend for any plan which uses opposed beams.  The AeroForm Tissue expander poses some unique challenges but with EZFluence we were able to get an optimal plan in a short amount of time,” said Scott Dube, Medical Physicist at Morton Plant Hospital, Clearwater, FL.

As part of the agreement, the companies are developing plans to collaborate and educate at key Radiation Oncology and Medical Physics society meetings throughout 2019.

About AirXpanders

Founded in 2005, AirXpanders, Inc. (www.airxpanders.com) designs, manufactures and markets innovative medical devices to improve breast reconstruction. The Company’s AeroForm Tissue Expander System, is used in patients undergoing two-stage breast reconstruction following mastectomy. Headquartered in San Jose, California, AirXpanders’ vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction.  AirXpanders is a publicly listed Company on the Australian Securities Exchange under the symbol “AXP.” AeroForm was granted U.S. FDA de novo marketing authorization in 2016, subsequent U.S. market clearance in 2017, first CE mark in Europe in 2012, and is currently licensed for sale in Australia.

About Radformation

Radformation is a team of medical physicists and medical device experts building software to automate workflow in cancer treatment. Radformation currently markets two FDA cleared products, including ClearCheck One-Click Plan Evaluation Software for radiation treatment plans, and EZFluence One-Click 3D Planning Software for intelligent automation of breast, brain, lung, and other 3D radiation treatment planning.  Radformation is privately held.

Forward-Looking Statements Regarding AirXpanders

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements.  These include, but are not limited to, the ability of EZFluence to improve acceptance of AeroForm, expected benefits to Radiation Oncology departments, the effectiveness of any treatment plans developed using the software, and the ease of use and adoption of EZFluence.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. AirXpanders may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements. For additional information and considerations regarding the risks faced by AirXpanders that could cause actual results to differ materially, see its most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 28, 2019, including under the caption “Risk Factors,” as well as other periodic reports filed with the SEC from time to time. AirXpanders disclaims any obligation to update information contained in any forward-looking statement, except as required by law. 

AirXpanders, Inc.	Radformation, Inc.
Laurel Burk Director, Marketing Tel: +1 (650) 390-9000 Email: lburk@airxpanders.com	Elisabeth Van Wie, MS, DABR Chief Business Officer Tel: 844-723-3675 x701 Email: evanwie@radformation.com

  

For more information on AeroForm or AirXpanders, Inc., please refer to the Company’s website at www.airxpanders.com

For more information on EZFluence or  Radformation, Inc., please refer to the Company’s website at www.radformation.com

Logo – https://mma.prnewswire.com/media/554207/AirXpanders_Logo.jpg
Logo – https://mma.prnewswire.com/media/847554/Radformation_Logo.jpg

Source: AirXpanders, Inc.

HONG KONG, April 4, 2019 /PRNewswire/ — The Cervical Cancer Screening Management System (CCSMS) developed by the Hong Kong Applied Science and Technology Research Institute (ASTRI) has won the Smart Living (Smart Healthcare) Silver Award at the Hong Kong ICT Awards 2019. The awards presentation ceremony, officiated by Mrs Carrie Lam — Chief Executive of Hong Kong SAR — took place on 4 April 2019.

ASTRI’s Cervical Cancer Screening Management innovation honoured at Hong Kong ICT Awards 2019

ASTRI’s CCSMS is a convenient, effective and accurate scalable computer-aided diagnostic platform. The CCSMS application enables the user to process and view medical images from different vendors and image formats, provides assistant diagnosis recommendations for the doctor’s reference. It also allows healthcare professionals to have remote medical diagnosis. The solution has been commercialised through one of the largest diagnostic service providers in the Mainland China and Hong Kong.

Health Technologies (HealthTech) form one of the five pillars in ASTRI’s innovation strategy. Commenting on this award-winning project, ASTRI’s CEO Mr Hugh Chow said, “Our HealthTech strategy aims to increase the efficiency of healer services, enhance and personalise medical services, and ultimately improve the quality of people’s lives. Through new applications of CCSMS, ASTRI works to contribute the improvement in Hong Kong’s healthcare industry and positively influence the city’s technological competence – for the benefit of its people.”

The Hong Kong ICT Awards was established in 2006 which aims at recognising and promoting outstanding information and communications technology (ICT) inventions and applications, thereby encouraging innovation and excellence among Hong Kong’s ICT talents and enterprises in their constant pursuit of creative and better solutions to meet business and social needs.

About ASTRI

Hong Kong Applied Science and Technology Research Institute Company Limited (ASTRI) was set up by the Government of the Hong Kong Special Administrative Region in 2000 with the mission of enhancing Hong Kong’s competitiveness in technology-based industries through applied research.

ASTRI’s core R&D competence in various areas is organised under seven Technology Divisions, namely Advanced Digital Systems, Communications Technologies, Electronics Components, Intelligent Sensing Technology System, Intelligent Software and Systems, Mixed Signal Systems IC and Security and Data Sciences. Our R&D strategic focus covers five areas of applications: financial technologies, intelligent manufacturing, health technologies, smart city, and Application Specific Integrated Circuits through our mandate as the Hong Kong branch of the Chinese National Engineering Research Centre (CNERC). Visit www.astri.org for more information.

Photo – https://photos.prnasia.com/prnh/20190404/2424823-1

SAN JOSE, California, April 4, 2019 /PRNewswire/ — AirXpanders, Inc. (ASX: AXP), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, today announced the publication of a large retrospective clinical study by Chopra, et al. which concluded that the use of AeroForm tissue expanders offers notable advantages for breast reconstruction.  The paper noted that when employed in the prepectoral space, the AeroForm device may be associated with reduced infection rates and decreased utilization of healthcare and patient resources.

The retrospective data are reported in an article titled, “Two-stage Prosthetic Prepectoral Breast Reconstruction: Comparing Tissue Expansion with Carbon Dioxide and Saline,” and appear in the March 25, 2019 online issue of the prestigious Plastic and Reconstructive Surgery – Global Open, an open access, peer reviewed, international journal focusing on global plastic and reconstructive surgery.  The principle author, Karan Chopra, is Chief Resident in the Department of Plastic & Reconstructive Surgery, Johns Hopkins University, Baltimore, MD.  Co-authors included Devinder Singh, MD, Chief of Plastic Surgery at Anne Arundel Medical Center, Annapolis, MD and Luther Holton III, MD from the Division of Plastic Surgery, Anne Arundel Medical Center, Annapolis, MD.

This study, the first of its kind to report on a novel breast expander technology combined with a newer reconstructive technique, is a retrospective analysis evaluating 115 patients with 185 breast reconstructions in a single institution.  Of these breast reconstructions, 74 (40%) utilized the AeroForm Tissue Expander, and 111 (60%) utilized traditional saline expanders.  Key findings in the paper included:

• The incidence of adverse events was greater in the saline group as compared to AeroForm (45.9% versus 32.4%)
• Post-operative wound infection was significantly more common in the saline group as compared with AeroForm (5.4% versus 0%)
• Full-thickness skin necrosis occurred at a significantly higher rate in the saline cohort as compared with AeroForm (5.4% versus 0%)
• The AeroForm cohort showed reduced time to expand versus saline (an average of 45 days versus 87 days) and reduced time to reconstruction (an average of 94 days versus 143)

The authors of the paper also noted, “The clinical benefits we have noted include the ability to expand gradually in less time, elimination of the risk of iatrogenic introduction of bacteria into the implant pocket, elimination of the chance for iatrogenic rupture during needlesticks, and the ability of the patient to expand at their own rate depending on the patient’s level of comfort.   The benefits from a patient care perspective include less burden on the patient for clinic visitation and decreased utilization of healthcare resources during the fill process.  Moreover, this expands the ability for breast centers to care for more patients since the time scheduled for expansions is eliminated and patients who live farther away require fewer visits for expansion.”

“These finding support the many advantages of the AeroForm System,” said Frank Grillo, President and CEO of AirXpanders, Inc.  “The data suggests that reducing multiple needlesticks may be a contributing factor in reducing rates of infection and the consistent weight of the gas-filled AeroForm Expander may explain the reduced necrosis rates.  This is significant for both the hospital and patient in terms of readmission costs and quality of care.”

About AirXpanders

Founded in 2005, AirXpanders, Inc. (www.airxpanders.com) designs, manufactures and markets innovative medical devices to improve breast reconstruction. The Company’s AeroForm Tissue Expander System, is used in patients undergoing two-stage breast reconstruction following mastectomy. Headquartered in San Jose, California, AirXpanders’ vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction.  AirXpanders is a publicly listed Company on the Australian Securities Exchange under the symbol “AXP.” AeroForm was granted U.S. FDA de novo marketing authorization in 2016, subsequent U.S. market clearance in 2017, first CE mark in Europe in 2012, and is currently licensed for sale in Australia.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements.  These include, but are not limited to, the advantages and benefits of AeroForm over existing technologies, and the significance of the study data to hospitals and patients.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. AirXpanders may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements. For additional information and considerations regarding the risks faced by AirXpanders that could cause actual results to differ materially, see its most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 28, 2019, including under the caption “Risk Factors,” as well as other periodic reports filed with the SEC from time to time. AirXpanders disclaims any obligation to update information contained in any forward-looking statement, except as required by law. 

AirXpanders, Inc.	Australia Distributor
Laurel Burk Director, Marketing Tel: +1 (650) 390-9000 Email: lburk@airxpanders.com	Spiran Adrian Magnera CEO Tel: +61 (08) 8132 03 00 Email: adrian@spiran.care

For more information, refer to the Company’s website at www.airxpanders.com.

Logo – https://mma.prnewswire.com/media/554207/AirXpanders_Logo.jpg  

Source: AirXpanders, Inc.

Customers to benefit from tax incentives alongside enhanced medical protection and prudent financial planning options suiting their diverse needs

HONG KONG, April 1, 2019 /PRNewswire/ — Leading financial services provider Manulife Hong Kong today unveiled a full suite of tax-deductible solutions tailored to enhance the health wellbeing and retirement preparedness of Hong Kong people. These comprise the certified Standard Plan and Flexi Plan under the HKSAR government’s Voluntary Health Insurance Scheme (VHIS), and the MPF Tax Deductible Voluntary Contributions (TVC) account. Manulife also announced the plan to introduce a certified Qualifying Deferred Annuity Policy (QDAP).

(From left to right) Wilton Kee, Chief Product Officer, Individual Financial Products at Manulife Hong Kong; Guy Mills, CEO of Manulife Hong Kong; Raymond Ng , Head of Employee Benefits at Manulife Hong Kong; and Ellen Leung, CEO of Manulife Provident Funds Trust Co., today celebrate the launch of the company’s new tax-deductible health and retirement offerings.

In his opening remarks, Guy Mills, CEO of Manulife Hong Kong, highlights the company’s strength and expertise in health protection and retirement planning, and how customers will benefit from the new offerings.

Together the new offerings will provide customers with enhanced protection, greater financial security and new tax benefits.

“Manulife is proud to be a top insurance brand and we value the importance of providing our customers with more insurance options for healthcare services and retirement planning. With the growth of aging population and the hike of medical cost in Hong Kong, we are pleased to offer our customers better coverage through the latest array of health and retirement solutions, which we are announcing today,” said Guy Mills, Chief Executive Officer of Manulife Hong Kong.

Stronger health protection with VHIS Plans

Manulife is at the vanguard of launching the VHIS Standard Plan and Flexi Plan, both certified by the Food and Health Bureau. The company’s Standard Plan, Manulife Shelter VHIS Standard Plan, and Flexi Plan, Manulife First VHIS Flexi Plan, deliver the VHIS scheme’s core benefits: coverage of unknown pre-existing conditions^[1]; guaranteed renewal; and no lifetime benefit limit, among many others.

The Manulife First VHIS Flexi Plan offers customers greater health protection through nine options, including different ward class choices and additional reimbursement amounts for excess medical expenses. Customers can enjoy extra protection with the plan’s unique benefit of up to 100% medical expenses reimbursement^[2]. They are also free to choose their preferred doctor or hospital for treatment.

“Our recent survey found that those without insurance protection expect to use their personal savings to pay over 80% of their medical bills in case of serious illness. That is a huge burden for most people and a significant stress to live with. We believe many Hong Kong people can fill this gap by buying the new VHIS plans while enjoying tax concessions,” said Mr. Mills.

Under the VHIS plans, eligible premiums can be tax-deductible for up to HK$8,000 per insured person per tax year. This benefit is also applicable to certified plans purchased for an unlimited number of eligible dependents.

Customers of Manulife’s VHIS plans can save even more through Manulife’s unique offerings. By becoming a member of ManulifeMOVE and staying active to achieve specified activity goals, customers will be rewarded with a premium discount of up to 10% upon annual renewal.

Boosting retirement savings with TVC and QDAP

The largest MPF scheme sponsor^[3], Manulife managed 23% of Hong Kong’s total MPF assets as of the end of 2018. Leveraging its pension expertise, Manulife’s TVC account will help the city’s working population boost their retirement savings while unlocking the new tax concessions. The maximum tax-deductible limit for TVC and QDAP premiums is set at HK$60,000 per taxpayer per tax year.

TVC account members will be provided with flexible options to make extra contributions, including the contribution amount, and payment on a monthly or lump sum basis^[4]. Manulife’s TVC account members will have a broad choice of MPF funds to pick from for their additional contributions. These new members will be automatically enrolled in Manulife’s MPF member rewards programme that offers privileged management fee rates for applicable constituent funds. The longer members stay and the more assets they maintain with Manulife, the better privileged rates they may enjoy^[5].

Manulife’s planned QDAP product is another choice for the city’s workforce to secure stable income in retirement. This tax-deductible annuity is expected to be launched shortly, subject to regulatory approval.

Buysimple.hk delivers new solutions to fingertips

The new offerings will be distributed through Manulife’s 8,800-strong agency force, whose advice and support are highly valued by the company’s 2.2 million customers in Hong Kong. Digital-savvy customers will enjoy the convenience and ease of buying VHIS plans or applying for MPF TVC directly online. These products will roll out on a one-stop shop www.buysimple.hk in phases, starting from today. Customers who buy online will be assigned a dedicated financial advisor to help with claims and other after-sales services.

Through www.buysimple.hk, customers can access a purpose-built tax savings calculator. By answering a few simple questions about their tax profile and providing the sum they intend to pay for the tax-deductible solutions, taxpayers receive an instant estimate on applicable tax breaks.  

For more details about the above offerings and the tax savings calculator, please visit www.manulife.com.hk.

About Manulife Hong Kong

Manulife Hong Kong, comprising Manulife (International) Limited, Manulife Asset Management (Hong Kong) Limited and Manulife Provident Funds Trust Company Limited, offers a diverse range of protection and wealth products and services to individual and corporate customers in Hong Kong and Macau. These entities are members of the Manulife group of companies. 

About Manulife

Manulife Financial Corporation is a leading international financial services group that helps people make their decisions easier and lives better. We operate primarily as John Hancock in the United States and Manulife elsewhere. We provide financial advice, insurance, as well as wealth and asset management solutions for individuals, groups and institutions. At the end of 2018, we had more than 34,000 employees, over 82,000 agents, and thousands of distribution partners, serving almost 28 million customers. As of December 31, 2018, we had over C$1.1 trillion (HK$6.2 trillion) in assets under management and administration, and in the previous 12 months we made C$29.0 billion in payments to our customers. Our principal operations in Asia, Canada and the United States are where we have served customers for more than 100 years. With our global headquarters in Toronto, Canada, we trade as ‘MFC’ on the Toronto, New York, and the Philippine stock exchanges and under ‘945’ in Hong Kong.

Photo – https://photos.prnasia.com/prnh/20190401/2419716-1-a
Photo – https://photos.prnasia.com/prnh/20190401/2419716-1-b

HONG KONG, April 1, 2019 /PRNewswire/ — FTLife Insurance Company Limited (Company registration number: 00028) today unveiled the “WiseCare” and “BetterCare” Medical Insurance Plans, following recent launch of the HKSAR Government’s Voluntary Health Insurance Scheme (“VHIS”).

FTLife launches the “WiseCare” and “BetterCare” Medical Insurance Plans being the first-batch of VHIS certified standard and flexi plans in the market

The new plans have been designed in line with FTLife’s commitment to providing customers with all-round health and medical protection.  “WiseCare” is a standard plan, while “BetterCare” is a flexi-plan (please refer to appendix) — and both will help prepare customers and their families to meet medical needs as they occur.

FTLife CEO Gerard Yang said: “The fact that people are becoming more health conscious has manifested itself as growing popularity around medical insurance products over the last 10 years — to the point market penetration is now approximately 34%^[1]. We believe demand for such products will rise dramatically because medical costs are escalating and Hong Kong’s public hospitals are under immense pressure.” 

He added: “We support launch of VHIS products as a positive step by the HKSAR Government and are honoured to become one of the first insurance companies authorised by the Food and Health Bureau to launch both standard and flexi plans simultaneously. It is also noteworthy that recent research^[2] shows close to 40% of respondents have expressed interest in applying for a VHIS plan. FTLife therefore sees significant potential in the future of medical protection products.”

Advantages of VHIS

According to the HKSAR Government, certified VHIS plans must meet certain minimum requirements, which include:

• Guaranteed renewal up to age 100  
• No lifetime benefit limit and deductible^[4]
• Covering unknown pre-existing conditions
• Covering confinement and day case procedure
• Covering prescribed diagnostic imaging tests^[5]
• Cancer treatment protection, including prescribed non-surgical cancer treatment^[6]
• Psychiatric treatment

Both “WiseCare” and “BetterCare” cover all the above items and extend all VHIS advantages to FTLife customers.

Pioneer Medical Support Service

Safeguarding customers’ health is FTLife’s first and foremost mission, which is exemplified by three major value-added services offered by “WiseCare” and “BetterCare” — cancer consultancy, cashless arrangement and specialist referral.

“WiseCare”provides extra protection up to the value of HK$300,000 

Comprehensive protection provided by “WiseCare” includes compassionate death benefit, additional death benefit for organ donor and medical negligence benefit totalling up to HK$300,000. This extra protection has been designed to lighten the financial burden on a beneficiary in the event of sudden death of the insured. 

“BetterCare” provides major medical benefit and up to 16% no claim discount
“BetterCare” offers enhanced protection that includes:

• Major Medical Benefit ^[8]: Additional benefit of 80% is available to meet expenses that exceed the maximum amount of basic benefit for major benefit items, providing the insured with peace of mind when receiving medical treatment on the road to recovery.
• No claim discount: No claim premium discount of 16% is granted in the first policy year; the discount applies to every policy year until such time as the first claim is made.

One-off migration arrangement provides customers with tax deduction

FTLife’s Chief Product Officer, Christine Yeung, said: “We are committed to providing customers with superior medical protection. We are among the few VHIS providers that offer both basic plan and rider for customers. Launch of our ‘WiseCare’ and ‘BetterCare’ VHIS certified plans at affordable premiums will now provide customers with more comprehensive medical protection plus tax deduction ^[9].”

She added: “As a responsible corporate citizen, we built a ‘caring for society’ element into our product design by introducing additional death benefit for organ donor. In addition, customers will be able to convert qualifying existing medical plans into a new VHIS certified plan for continued all-round protection — and get tax deduction.”

Get up to 3 month first-year premium refund plus a free health check

FTLife’s Chief Marketing Officer, Angela Yam, said: “FTLife serves our valued customers as their ‘health manager’ because we believe good health leads to a brighter future. With this in mind, from now until 30 June, if the number of eligible family member ^[10] meets the designated requirement, customers will be entitled up to 3 month first-year premium refund upon successful application of ‘WiseCare’ and ‘BetterCare’.”

She added: “In a move to encourage our customers to lead healthy lifestyles, we would like to offer free ‘Advanced Health Test for Urbanite” ^[11] when a customer meets a designated first-year annualised premium requirement by successfully applying for at least one designated VHIS plan or health protection plan.”

Remarks:

1. Third issue of the Research Brief for 2017-2018 on “Health insurance for individuals in Hong Kong” by the Research Office of the Legislative Council Secretariat, July 2018.
2. Research findings from “Market Research Growth Opportunities in 2019” by the Hong Kong Federation of Insurers.
3. Food and Health Bureau’s VHIS website: https://www.vhis.gov.hk/en/about_us/scheme.html
4. Except 30% coinsurance for prescribed diagnostic imaging tests and 20% coinsurance on major medical benefits (applicable to “BetterCare”) which must be borne by the policyholder, no deductible for other benefit items.
5. Prescribed diagnostic imaging tests include computed tomography (“CT” scan), magnetic resonance imaging (“MRI” scan), positron emission tomography (“PET” scan), PET-CT combined, and PET-MRT combined. 
6. Prescribed non-surgical cancer treatment includes radiotherapy, chemotherapy, targeted therapy, immunotherapy and hormonal therapy. 
7. Find out more about “Pioneer Medical Support Service” by referring to the “Pioneer Medical Support Service” promotional flyer or company website at https://www.ftlife.com.hk/en/products/life-insurance/health/VHIS-series.html.
8. Major medical benefit is subject to maximum reimbursement of different benefit levels. Please refer to the terms and benefits.
9. Tax deduction is applicable only to a policyholder who holds a valid identity card issued by the HKSAR Government.
10. Family members include (i) the insured him/herself; (ii) his/her spouse and children; or (iii) the insured’s and his/her spouse’s parents, grandparents or siblings. Please refer to the relevant incentive flyer for details.
11. The “Advanced Health Test for Urbanite” is subject to Terms & Conditions governing the incentive scheme. Eligible policyholders can choose one of the following — automatic retinal image analysis (ARIA) vascular health stroke risk screening or HPV DNA genotyping screening or colorectal cancer screening. Please refer to the incentive flyer for details.

Important notes: 

• Information contained in this document is intended as a general summary of information for reference only. Please refer to the relevant product brochure and client incentive leaflet for details of “WiseCare” and “BetterCare”. Please refer to the policy provision for full details of Terms & Conditions. For further information, please contact your FTLife consultant or call FTLife’s Customer Service Hotline on 2866 8898. 
• You can also find out more about the VHIS by visiting the Food and Health Bureau’s VHIS website (see remark 3 above).
• This document is for distribution in Hong Kong only. It is not an offer to sell or solicitation to buy or provision of any insurance product outside Hong Kong. FTLife does not offer or sell any insurance product in any jurisdiction outside Hong Kong, in which such offering or sale of the insurance product would be illegal under the laws of such jurisdictions.

About FTLife Insurance Company Limited 
FTLife Insurance Company Limited (“FTLife”) is one of Hong Kong’s most well-established life insurance companies. Capitalising on a heritage of professionalism and excellence in serving clients, FTLife seeks to become a leading insurance group in Asia. It serves individual and institutional clients from a diverse portfolio of financial protection and wealth management products. FTLife aims to excel by cultivating lasting relationships and dedicates itself to providing clients with best-of-breed financial services to help them lead fulfilling lives. 

Media inquiries 
FTLife Insurance Company Limited 
Branding, Marketing & Communication 
Tel: +852 2591 8888   
Email: ftlhk.mkt@ftlife.com.hk

Appendix — “WiseCare” and “BetterCare” at a glance

Photo – https://photos.prnasia.com/prnh/20190401/2419975-1

HONG KONG, March 30, 2019 /PRNewswire/ — A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2018 (the “Year”), as well as its comparatively figures for the year ended 31 December 2017 (“2017”).

Key Accomplishments in 2018

During the Year, the Group has recorded a spectrum of accomplishments, either in terms of marketed products, or consolidation of the Group’s assets. The key highlights include:

1. During the Year, the Group’s investments and efforts in marketing team’s integration and optimization, especially expanding the sales capacity for its biologic drugs, notably GeneTime^® and GeneSoft^®, have begun to bear fruit. The extended coverage into tier-3 hospitals, primary healthcare centres, and community hospitals has greatly fuelled the revenue growth of the Group. These two products have seen growth both in their average selling price and sales volume, totaled at HK$72.5 million and HK$31.3 million, representing an increase of 9.2% and 49.4% respectively.
2. During the Year, Pinup^® (commonly known as voriconazole tablets) successfully tapped into the Guizhou, Xinjiang, Shaanxi and Hainan market and expanded its coverage to 26 provinces. The Group also entered into a cooperation agreement for Pinup^® National Promotion Project with Shanghai Loymed Pharma Technology Co., Ltd. (“Loymed Pharma”). Under the Agreement, Loymed Pharma was granted the exclusive agency right to market, promote, distribute and sell the contract product in the PRC. The Group believes that partnering with Loymed Pharma, who enjoys extensive distribution network in the PRC market, it will continue to expand the market coverage of Pinup^® in order to fully realize its market potential.
3. The Group has completed the BE study of Acarbose tablet and is in the view that BE results are robust. The abbreviated new drug application (“ANDA”) together with related BE study results were submitted and accepted by the NMPA in December, 2018. In addition, the Group’s another self-developed biologic drug tailored for patients living with Type 2 diabetes, Recombinant Exendin-4 Injection (“2nd Generation Uni-E4”), has been accepted by the CDE of NMPA for Phase III clinical trial during the Year. 
4. The Group’s newly launched product Bokangtai (Mitiglinide tablets) also concentrates on the treatment of Type 2 diabetes. During the Year, Bokangtai added ten more provinces into its distribution network, namely Shandong, Guangxi, Xinjiang, Qinghai, Ningxia, Hainan, Sichuan, Guizhou, Yunnan and Guangdong. Currently, the Group is collaborating with Jiangsu Hansoh Pharmaceutical Group Co., Ltd. to jointly conduct the BE study on Bokangtai. The preparation work was commenced and the BE online registration will be submitted in the second half of 2019. Approval is expected to be obtained in 2020.
5. To fully harness asset values, the Group set up two state-of-the-art aseptic production lines to support the development of the 2nd Generation Uni-PTH and Uni-E4 injection-form products, and currently the production lines are put into operation of Contract Manufacturing Organization (“CMO”) services. The Group has also launched the 3-in-1 CMO customizing services solution, which could collaborate strategically with client base on the distinctiveness of R&D of new drugs and the respective production process, hence to offer quality and efficient CMO production services.
6. During the Year, the Group strategically completed a series of non-core asset disposal and asset structure optimization, including the divestiture of non-core R&D projects by offloading the chemistry, manufacturing, and controls (“CMC”) platform with its related facilities and joint management of fixed assets, thereby improving management efficiency, revitalizing asset portfolios, streamlining business operations, and focusing on core businesses. The Group believes that such disposal will benefit more on developing, manufacturing and distribution of innovative biological pharmaceutical products.
7. Uni-PTH, namely its powder famulation, the only anabolic agent effective in improving bone density, is marching towards its official launch. The Group has been taking proactive actions to proceed with the launch timetable of Uni-PTH and actively preparing for its NMPA’s on-site inspection. Meanwhile, through constructive communication with CDE, both sides came to a conclusion that the clinical trial of the liquid form of Uni-PTH is to be exempted, thus, it will proceed into BE study in the near term.

Annual Results

In 2018, the Group recorded a turnover of HK$135.3 million, representing a decrease of 13.6% YoY. The decrease in turnover was mainly attributable to the consistent R&D investment and weaker sales situation for one of the Group’s marketed drugs, namely Pinup^®. R&D costs proportionate to revenue increase from 27.2% for 2017 to 32.7% for the Year to progressing our Biological innovation projects as EGF products, Uni-E4 and Uni-PTH, meanwhile, Pinup^® faced keener price competitions across the marketplace where other market players lowered the product price, hence the sales was temporarily affected. However, sales of Pinup^® had begun to pick up towards the end of the Year, thanks to its increased coverage to the total 26 provinces in PRC. Given that the Group’s major competitors who are engaged with price war in the market have not conducted BE study, obtaining the approval will allow the Group to enjoy numerous policy benefits during tendering and purchasing.

Gross profit decreased by 12.0% to approximately HK$117.6 million (2017: HK$133.6 million), on the contrary, gross profit margin improved slightly from 85.4% in 2017 to 86.9% in 2018, led mainly by the increase of overall unit sales price of GeneTime^®. Alongside our efforts for restructuring and reorganizing our sales team in order to achieve greater efficiency, the Group also expanded the number of sales team members. Hence the sales and distribution cost recorded an increase over the Year.

In 2018, the Group recorded a loss of HK$120.6 million with a basic loss per share of HK$2.24 cents for the Year. The increase in loss was mainly caused by this reason: we have seen mounting pressure on the pricing of Pinup^®, hence the Group has been optimizing its salesforce since last year in an effort to achieve maximum sales efficiency. The sales team has been expanding rapidly, and the distribution channels have also expanded significantly leading to a higher cost in the short term. By the time the Group secure the threshold of drug consistency evaluation, which should be by 2020, more resources will be deployed on marketing and distributing Pinup^®. This should bring promising revenue in the near future.

Prospects

Looking forward to 2019, in the face of rising pressure on tendering price cut, as well as the escalating trade tension between the United States and China, the Group remains in the view that innovation, business diversification and efficient resource allocation could promise stability despite regulatory pressure and political risks. The expanding aging population, along with the increasing health awareness of people, should also lay a foundation for pharmaceutical companies with expertise in specific diseases to thrive. Diabetes has become increasingly prevailing during the past decade. According to the International Diabetes Federation, there was a total of 425 million adults with diabetes worldwide last year. It is predicted that the population of diabetes patients will grow rapidly in the next 30 years. Within which PRC is expected to be accounted for approximately 48% of the population. Under such favourable factors, The Group is of the belief that market sentiment over healthcare sector will recover in the near future, and hence creating to a stable development environment for the Group.

Mr. Kingsley Leung, Chairman of Uni-Bio Science, commented “In 2018, our Group witnessed a series of policy rollouts with the pharmaceutical peers in China – capacity upgrade and optimization, reshuffling of business channels, new regulations in the capital market that have reshaped the wider marketplace. Faced with these uncertainties, the Group still strived to enhancing our revenues, albeit yet to reach a turnaround in profit, we have laid a solid foundation to harvest the fruits we cultivated previously. Our chemical products, including antifungal and Type II diabetes drugs, would likely to obtain BE approval as scheduled. Innovative biologic drugs in the pipeline and clinical trials have received positive feedback from the CDE and assured of our launch schedule. We partnered two capable parties to deeply explore market potentials, and more investment institutions and investors have come to realized that the Group’s values have been underestimated. Our new production lines can support mass production of injection products apart from taking up more CMO tasks. Going forward, we will continue to push the launch of new drugs and exercise efficient control on costs. We will continue with our business philosophy, to offer more pharmaceutical solutions to the China market with regard of endocrinology and related fields.”

–END–

About Uni-Bio Science Group Limited

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments and innovative drugs addressing the therapeutic areas of diabetes, ophthalmology and dermatology.

Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.

This press release is issued by DLK Advisory Limited for and on behalf of Uni-Bio Science Group Limited.

For further information, please contact:

DLK Advisory
Michelle Shi (michelleshi@dlkadvisory.com) 
Linda Liang (lindaliang@dlkadvisory.com) 
Cathy Wu (cathywu@dlkadvisory.com) 
Max Lau (maxlai@dlkadvisory.com) 
Tel: +852 2857 7101 
Fax: +852 2857 7103

Uni-Bio Science Group Limited

CAMBRIDGE, Mass. and SHANGHAI, March 30, 2019 /PRNewswire/ —  WuXi NextCODE, a global genomic data and insights company, is expanding its laboratory footprint into the U.S. with the opening of a state-of-the-art, CLIA-certified and CAP-accredited genetic analysis laboratory in Woburn, Massachusetts.  The new laboratory is geographically close to WuXi NextCODE’s U.S. office in Cambridge, Massachusetts.

“This new laboratory helps us provide our customers with the access to next generation sequencing for clinical trials around the world, under the roof of one single, highly respected organization,” says Rob Brainin, Chief Executive Officer of WuXi NextCODE. “Our global lab footprint also ensures a seamless unified workflow with a single chain of custody, from sample management, standard operating procedures, rigorous implementation of quality systems, to analytics and standardized reporting, in the U.S., Asia and the E.U.”

As the first CAP/CLIA/ISO 15189 certified laboratory in China, the company’s Shanghai laboratory already offers comprehensive next generation sequencing (NGS) clinical and discovery research services. WuXi NextCODE has also recently acquired a large scale NGS laboratory in Dublin, Ireland, which is already CAP-accredited and anticipated to be CLIA-certified in the third quarter of 2019.

The first oncology panel to be offered in the U.S. lab’s CLIA/CAP environment will be Illumina’s new TruSight Oncology 500^™ (TSO 500), which is a comprehensive pan-cancer tumor profiling assay that can support prospective patient enrollment in clinical trials, retrospective exploratory translational research and biomarker discovery applications. The TSO 500 research use only (RUO) test provides comprehensive coverage of established and emerging oncology biomarkers with the ability to provide rapid turnaround time. The panel will initially be offered at WuXi NextCODE’s newly opened U.S. laboratory and then launched across the company’s other global laboratories in Shanghai and Dublin.

TSO 500’s comprehensive, integrated next-generation sequencing assay combines a DNA+RNA workflow (when bundled with the TruSight ^™ Tumor 170 RNA panel) from the same FFPE tumor-only sample to accurately, reproducibly and comprehensively identify key somatic variants underlying tumor progression. These variants include DNA variants across 523 genes (including SNVs, indels and copy number abnormalities), and gene fusions and splice variants from the integrated RNA assay of 55 genes. Notably, TSO 500 also measures tumor mutational burden (TMB) and microsatellite instability (MSI), features that are potentially key response biomarkers for immune-based therapies. WuXi NextCODE’s deployment of the TSO 500 assay allows users full access to raw genomic data for further analysis and future use, in addition to robust standardized variant reporting.

“We are very pleased to supply WuXi NextCODE with Illumina’s TruSight Oncology 500 assay to enable the company’s translational research customers,” says Garret Hampton, Ph.D., Senior Vice President of Clinical Genomics at Illumina.  “We expect that the use of TruSight Oncology 500 will lead to robust biomarker discovery, while also directly supporting oncology-focused therapeutics and companion diagnostic development.”

“This assay’s comprehensive genomic footprint, speed, accuracy, sensitivity and convenience make it a true game changer in our ability to support our customers’ comprehensive oncology panel profiling needs – whether it be for patient selection or stratification in clinical development programs or for biomarker discovery,” says Richard Williams, MB BS, PhD and Managing Director and Head of Oncology at WuXi NextCODE.  “We are well prepared to help our clients navigate this sometimes-challenging road to regulatory approval for a biomarker-guided cancer treatment, and TSO 500 is central to our strategy to enable our partners to bring the next generation of cancer drugs to patients in need.”

About WuXi NextCODE
WuXi NextCODE is a global genomic data and insights company with operations in Kendall Square, Cambridge, Massachusetts, and in Dublin, Reykjavik and Shanghai. We serve the world’s leading life sciences companies including biotechnology, pharmaceutical companies and medical research centers. Our partners all use insights from genomic data to improve health. Our capabilities include providing access to population-scale patient cohorts for research, next generation sequencing (NGS) CLIA/CAP GCP labs globally, and a team of the world’s leading A.I. and genomic analysis experts and technologies for organizing, mining and sharing genomic and disease biology data. Visit us on the web at wuxinextcode.com.

Meet us at AACR 2019. Find us at booth 3114, or at our presentation and posters to learn more about our full suite of genomic tools and services.

View original content:http://www.prnewswire.com/news-releases/wuxi-nextcode-launches-new-state-of-the-art-genetic-analysis-laboratory-in-us-with-illuminas-new-trusight-500-assay-300821439.html

BEIJING, March 30, 2019 /PRNewswire/ — Cardinal Health (NYSE: CAH) today unveiled its new Chinese name – Jia De Nuo at gathering of China’s leading cardiologists in Beijing. In Chinese, “Jia” means auspicious and happy, “De” represents ethics, and “Nuo” is promise, which reflects Cardinal Health’s deep commitment to meeting the needs of healthcare providers and patients in China.

Speaking at the name unveiling ceremony, Jessie Lian, General Manager of Cardinal Health China, said “Cardinal Health is a global leader in medical products with almost 100 years of experience and expertise in delivering high quality, clinically proven solutions that improve the lives of patients. We are committed to fostering strong local partnerships that will allow us to provide tailored products and solutions to the physicians, nurses and patients we serve in China.”

Left to right: Jessie Lian, Professor Junbo Ge, Professor Shubin Qiao, Professor Shaoping Nie

Ms Lian along with the country’s top cardiologists – Professor Junbo Ge, Academician of the Chinese Academy of Sciences, Director of Cardiology Department of Zhongshan Hospital, Professor Shubin Qiao, Chief Physician of Coronary Heart Disease Center of Fuwai Hospital, and Professor Shaoping Nie, Head of Emergency and Critical Care Center of Beijing Anzhen Hospital, jointly unveiled the new name, Jia De Nuo, at the launch event.

Over the last few years, Cardinal Health has taken strategic steps to expand its business footprint in China. Continued investment in Cardinal Health’s Cordis business has positioned the company for growth, offering trusted innovation in the cardiovascular space to enhance local patient care. Following the divestiture of its China distribution business in 2018, Cardinal Health China completed the integration of the Patient Recovery business from Medtronic in 2019, diversifying and increasing the depth of its medical products portfolio. These moves have enhanced Cardinal Health’s ability to supply China’s healthcare providers with a portfolio of high-quality products and solutions that span the entire continuum of care.

Professor Shaoping Nie stated, “Modern healthcare model is constantly transforming. It is an evoloving process that companies, healthcare providers and us physicians need to continuously embrace. What is not changing are the shared values and promises we made to the patients. With the new chapter of Cardinal Health China, through the shared promises, I look forward to working more closely together in our shared combat towards a healthier future for our patients.”

This year also marks the 60^th anniversary of the establishment of Cordis. Professor Shubin Qiao commented, “Being one of the pioneers in the development of interventional vascular products and technology, Cordis has played a critical role in delivering leading products to treat many patients as well as in providing clinical trainings to many physicians in China.”

“1 in 5 adults has cardiovascular disease in China and the prevalence rate is still rising at a rapid pace. It is a major public health issue that can only be better managed through collaborations amongst all parties.” Professor Junbo Ge stated, “We have made great progress in the past years and we appreciate partners, such as Cardinal Health, to continuously support the development of cardiology in China.”

About Cardinal Health 

Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically proven medical products, pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. To help combat prescription drug abuse, the company and its education partners created Generation Rx, a national drug education and awareness program. Backed by nearly 100 years of experience, with approximately 50,000 employees in nearly 46 countries, Cardinal Health ranks #14 on the Fortune 500. For more information, visit cardinalhealth.com, follow @CardinalHealth on Twitter, @cardinalhealthwings on Facebook and connect on LinkedIn at linkedin.com/ company/cardinal-health.

About Cordis

Cordis, a Cardinal Health company, is a worldwide leader in the development and manufacture of interventional vascular technology. As of 2015, Cordis is a part of Cardinal Health, bringing together two important players in the healthcare industry and creating an unmatched combined offering in the cardiovascular space that will ensure greater access to quality products and services worldwide. Cordis is committed to equipping physicians with products that truly addresses clinical needs so that they can bring better outcomes for the patients. For the past 20 years in China, Cordis has been a trusted partner for healthcare professionals in the field of vascular intervention in China, and is committed to continue contributing for the future transformation and development of the industry.

Photo – https://photos.prnasia.com/prnh/20190330/2419647-1

Continued to strengthen its leading market position and execute diversified services strategy

Revenue and core net profit* increased by approximately 42% and 26% respectively

HONG KONG, March 29, 2019 /PRNewswire/ —

Financial Performance:

* Excluding the effect of the listing expenses

Operational & Development Highlights:

Rapid growth in scale expansion in property management service segment

• Revenue from property management service segment amounted to RMB453 million with a growth rate of 42.6%, accounting for approximately 73.2% of total revenue
• By the end of 2018, the Group had a total GFA under management of approximately 10.4 million sq.m., while the total GFA under management reached 11.22 million sq.m. in March 2019
• Revenue from South China region accounted for 66.7% of total revenue; the Group will continue to benefit from policy for Guangdong-Hong Kong-Macao Greater Bay Area
• The CAGR of the contracted sales of the parent company reached 89% with total GFA of land bank of 34.10 million sq.m. The Group’s GFA under management would greatly increase with the support of the parent company

Outstanding performance of commercial operational service segment 

• Revenue from commercial operational services amounted to RMB166 million with a growth rate of 40.3%, accounting for approximately 26.8% of total revenue. In which, revenue from commercial operation and management services increased substantially by 106.9%
• Provided commercial operational services to 9 shopping malls in operation with GFA under management of approximately 424,000 sq.m. and contracted to provide the commercial operation and management services to 25 shopping malls with contracted GFA of approximately 1.3 million sq.m.

Diversified business drives the long-term growth

• Apply two ecospheres of “lives in properties and commercial complex” thoroughly
• Grasp the opportunities in medical beauty market and establish the strategic cooperation with Genius Kabuskiki Kaisha and Beijing Chunyu Yisheng
• Create the first MS ARORA Wanbo flagship store
• Aoyuan Chinese Medicine provided “Community + Traditional Chinese Medicine” services in the communities
• “Aoyuejia” mobile application served about 27,700 property owners in 56 residential properties managed by the Group

Connecting with the capital market with rapid growth momentum 

• Separately listed in the Main Board of Stock Exchange of Hong Kong and broadly supported by international and local investors with net proceeds from the global offering of approximately HK$580 million
• Make good use of capital to accelerate business development and enhance long-term return to shareholders. Approximately 62.0% of raised funds will be used for strategic acquisition, investment opportunities and expansion of scale of commercial operational service and property management service businesses 

Aoyuan Healthy Life Group Company Limited (“Aoyuan Healthy” or the “Group”; SEHK stock code: 3662), is pleased to announced its annual results for the year ended 31 December 2018 (the “Year”).

Left to right: Chief Financial Officer and Director of Financial Management Division, Mr. Xu Xiaodong, Executive Director, Mr. Tao Yu, Chairman of the Board and Non-executive Director, Mr. Guo Zining, Non-executive Director, Mr. Chen Zhibin and Chief Operating Officer

Leveraging on the Group’s rich experience in property management and long-term and stable cooperation with the parent company, China Aoyuan Group Limited (“China Aoyuan” or the “parent company”; SEHK stock code: 3883), also with the joint efforts of all the management and employees, the Group achieved a leap-forward growth in the past few years and greatly improved its various operational indicators, which has laid a foundation for the Group to become a leading provider of property management and commercial operational services in China.

For the year ended 31 December 2018, the Group’s total turnover was RMB618.8 million, representing an increase of 41.9% compared to RMB436.0 million for 2017. The increase was mainly due to the rapid growth in GFA under management and commercial operational services. Turnover generated from property management services and commercial operational services contributed to 73.2% and 26.8% of total revenue, respectively.

The gross profit was approximately RMB208.8 million, representing an increase of approximately 40.6% as compared to that in 2017. The gross profit margin was 33.7% which remained stable. The Excluding the effect of the listing and related expenses of approximately RMB15.5 million (2017: RMB4.6 million), the Group’s core net profit was approximately RMB93.8 million, representing an increase of 25.7% as compared to that in 2017. Profit attributable to equity Shareholders was approximately RMB78.1 million in 2018 (2017: RMB69.8 million). Basic earnings per share is RMB0.1654.

The Board recommended the payment of a final dividend of RMB0.055 per share for the year ended 31 December 2018.

Property Management Services

For the year ended 31 December 2018, revenue from property management service segment amounted to RMB453 million with a growth rate of 42.6%, accounting for approximately 73.2% of total revenue. The Group achieved an increase in the GFA under management of 1.8 million sq.m. during the Year.

As at 31 December 2018, the Group provided property management services to 61 properties in 25 cities across 11 provinces, municipalities and autonomous regions in the PRC with a total GFA under management of approximately 10.4 million sq.m. The Group’s total GFA under management reached to approximately 11.22 million sq.m. in March 2019.

The increase of revenue generated from property management services was approximately RMB70.9 million or approximately 30.2% and the increase in revenue generated from sales assistance services of approximately RMB55.0 million or approximately 125.3%. The increase of revenue generated from property management services was mainly due to the increase in the GFA under management from 8.6 million sq.m. to 10.4 million sq.m. The increase of revenue generated from sales assistance services was mainly due to the increase in number of properties we served from 54 in 2017 to 93 in 2018.

Commercial Operational Services

During the Year, revenue generated from commercial operational services was approximately RMB166 million with a growth rate of 40.3%, accounting for approximately 26.8% of total revenue. The growth was mainly attributable to the increase in revenue generated from commercial operation and management services of approximately RMB53.0 million or approximately 106.9%. 3 out of 4 newly opened shopping malls in 2018 were under the commercial operation and management services by the Group. Such shopping malls increased commercial operational services contracted GFA by approximately to 157,000 sq.m..

As at 31 December 2018, the Group provided commercial operational services to 9 shopping malls in operation with GFA under management of approximately 424,000 sq.m. and contracted to provide commercial operational services to 25 shopping malls with contracted GFA of approximately 1.3 million sq.m.

For the year ended 31 December 2018, revenue generated from market positioning and business tenant sourcing services was primarily attributable to the opening of Chongqing Chayuan Aoyuan Plaza, Zhuhai Aoyuan Plaza, Kangwei Plaza and Foshan Aoyuan Plaza; and the completion of a supplemental services contract for Shenyang Aoyuan Plaza.

Diversified Services – Healthcare Services

During the Year, the Group has seized the opportunity to enter the big health industry and promoted medical beauty services. It applied diversified services in two ecospheres of “lives in properties and commercial complex” and continuously integrated resources to provide medical beauty services and traditional Chinese medicine services for customers. The Group created a “light medical beauty” concept of “professional medical beauty is around you” for the medical beauty service of Aoyuan, and develop the medical beauty service segment, with the grand opening of the first MS ARORA Wanbo flagship store on 15 March 2019. The Group was dedicated to creating the service mode of “community + traditional Chinese medicine” for the traditional Chinese medicine service segment, so as to introduce healthier lifestyle and idea of traditional Chinese medicine to communities, and to lay foundation of elderly care services in communities.

O2O Platforms

In response to demands from property developers, property owners, residents and tenants, our Group has made efforts to optimize our business model and improve our service quality. Our O2O platforms primarily comprise our “Aoyuejia” Android and iOS mobile application and WeChat official accounts. Our Group launched “Aoyuejia” mobile application in June 2017 which is designed to meet the diversified demands of our residents at the residential communities we manage. As at 31 December 2018, “Aoyuejia” mobile application covered 56 residential properties managed by us, and had approximately 27,700 registered users.

Future Outlook

The Group plans to strengthen our position in the property management service and commercial operational service industries by implementing the following strategies: (i) benefited from the parent company’s repaid development to enhance service quality and expand the property management service portfolio; (ii) scale up the commercial operational service business with a focus on the Greater Bay Area and across the PRC; (iii) further develop the healthcare services and integrate with the existing business to create synergy and achieve collaborative development; (iv) continue to develop and upgrade our O2O platforms to enhance our customers’ experience and facilitate the establishment of a big data analytics platform; and (v) develop intelligent service systems and upgrade our internal IT system to enhance operational efficiency.

Mr. Guo Zining, Chairman of the Board and Non-executive Director said, “Looking ahead, with the increasing competition among industry, the Group will leverage its strengths to expand the property management portfolio and plan to focus its future development on cities with large population and large growth potential. In addition, the Group will continue to develop and upgrade online and offline platform, and enhance customers’ experience and establish big data platform, develop high-technological service system, in order to enhance the Group’s competitiveness. Aoyuan Healthy will continue to implement a diversified development strategy, with support from China Aoyuan and actively gasp the opportunity to enter the health industry under national policy, to provide value-added services to customers, and accomplish the Group’s industry layout. Aoyuan Healthy will integrate the resources of property management services, commercial operational services and healthcare services to create synergy and achieve collaborative development.”

About Aoyuan Healthy Life Group Limited

Aoyuan Healthy Life Group Limited is a reputable property management service and commercial operational service provider in the PRC offering diversified property management services for residential and non-residential properties and a full range of commercial operational services for shopping malls, with a focus on mid to high-end properties and mixed-use property developments. The Group has also offered general health and wellness services for residents in order to build a community of traditional Chinese medical services and medical beauty services, develop diversified value-added services to enhance customer satisfaction.

Photo – https://photos.prnasia.com/prnh/20190329/2418776-1

CHENGDU, China and SEATTLE and IRVINE, California, March 28, 2019 /PRNewswire/ — Biokin Pharmaceutical Co. Ltd., (“Biokin Pharma”) a leading pharmaceutical company with operations in China and U.S., and Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Cryoport”), the world’s leading temperature-controlled logistics company dedicated to the life sciences industry, today announced Cryoport’s full suite of temperature-controlled solutions will support Biokin Pharma’s pending Phase I and II clinical trials in immuno-oncology in both the U.S. and China.

Biokin Pharma, is a biopharmaceutical company based in China focused on the treatment of cancer through developing novel therapeutic antibodies and antibody-drug conjugates (“ADC”s). Led by a group of highly experienced immuno-oncology scientists, the company utilizes several technology platforms to develop world class advanced antibody-based drug therapies. Its wholly-owned subsidiary SystImmune Inc. (“SystImmune”), which is funded in part by OrbiMed, was formed to advance its mission in the United States. Partnering with Cryoport will enable Biokin Pharma and SystImmune to utilize Cryoport’s full range of temperature-controlled logistics solutions to support its drug manufacturing processes across the globe. These solutions include the Cryoport Express® shippers, the industry-leading Cryoportal™ Logistics Management Platform, Smartpak II™ Condition Monitoring System and 24/7/365 logistics support.

“We are pleased to choose the highly reliable condition- and time-sensitive logistics solutions provided by Cryoport to support our upcoming clinical studies using Bispecific and Multi-specific Antibody, ADC, and T-cell Therapy,” said Dr. Yi Zhu, Chairman of Biokin Pharma and its U.S. subsidiary, Systimmune of Seattle, WA. “By relying on Cryoport’s excellent solutions, Biokin Pharma and Systimmune will continue to have the best possible viability and recovery of critical cells, vectors, antibodies and other materials, even after time-consuming international or domestic transportation, to ensure the best outcome for our patients.”

“As the regenerative medicine market rapidly matures, the demand for our technology-driven solutions to support trials across the globe is growing. We look forward to working alongside Biokin Pharma and its U.S. subsidiary to ensure reliable, secure logistics support for their temperature-sensitive commodities as they advance the development of potentially life-saving therapies,” said Mark Sawicki, PhD, Chief Commercial Officer of Cryoport.

About Biokin Pharma

Biokin Pharma researches and develops innovative therapies in immuno-oncology for cancer patients worldwide using targeted antibody, ADC, and cell therapy. For 2019 to 2020, Biokin expects to start four clinical trials in the U.S. and China using its SI-B001, SI-B003/032, GNC-038/039 therapies. One of the industry’s leading biopharma companies, Biokin Pharma was founded in 1996 by Dr. Yi Zhu with GMP R&D and manufacturing facilities in China and a US subsidiary- Systimmune Inc in Seattle WA. Biokin and Systimmune today have a leading portfolio of medicines targeting Epithelial Tumor, Non-small cell lung cancer, blood cancer, solid tumor, and other indications. 

For more information, visit http://www.baili-pharm.com or http://www.systimmune.com.

About Cryoport, Inc.

Cryoport is the life sciences industry’s most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR T-cells. Cryoport’s solutions are used by points-of-care, CRO’s, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport’s proprietary Cryoport Express® Shippers, Cryoportal® Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts. Cryoport is dedicated to: simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting; delivering the most advanced temperature-controlled logistics solutions for the life sciences industry; and providing vital information that provides peace of mind throughout the life of each logistics process.

For more information, visit www.cryoport.com. Sign up to follow @cryoport on Twitter at www.twitter.com/cryoport.

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company’s cash flow, market acceptance risks, and technical development risks. The Company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the Company’s SEC reports including, but not limited to, the Company’s 10-K for the year ended December 31, 2018 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Logo – https://mma.prnewswire.com/media/371732/cryoport_Logo.jpg  

Source: Cryoport, Inc.